Integration of Novel Agents into the Care of Patients with Multiple Myeloma.

@article{Orlowski2016IntegrationON,
  title={Integration of Novel Agents into the Care of Patients with Multiple Myeloma.},
  author={Robert Z. Orlowski and Sagar Lonial},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 22},
  pages={5443-5452}
}
The pace of therapeutic drug development in multiple myeloma has reached unprecedented levels, with five regulatory approvals for relapsed and/or refractory disease of either new drugs or new drug regimens in 2015, one already in 2016, and still others anticipated. This has provided a wide array of options to be considered by patients and their health care providers in the event of relapse after or progression on front-line therapy. Most of these agents are currently being evaluated in earlier… CONTINUE READING